🚀 VC round data is live in beta, check it out!
Monopar Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Monopar Therapeutics and similar public comparables like Formycon, PureTech Health, Ever Supreme Bio Technology, Climb Bio and more.
Monopar Therapeutics Overview
About Monopar Therapeutics
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Founded
2014
HQ
Employees
16
Website
Sectors
Financials (LTM)
EV
$247M
Monopar Therapeutics Financials
Monopar Therapeutics reported last 12-month revenue of — and negative EBITDA of ($23M).
In the same LTM period, Monopar Therapeutics generated — in gross profit, ($23M) in EBITDA losses, and had net loss of ($19M).
Revenue (LTM)
Monopar Therapeutics P&L
In the most recent fiscal year, Monopar Therapeutics reported revenue of — and EBITDA of ($17M).
Monopar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($23M) | XXX | ($17M) | XXX | XXX | XXX |
| Net Profit | ($19M) | XXX | ($14M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Monopar Therapeutics Stock Performance
Monopar Therapeutics has current market cap of $388M, and enterprise value of $247M.
Market Cap Evolution
Monopar Therapeutics' stock price is $57.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $247M | $388M | 0.3% | XXX | XXX | XXX | $-2.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMonopar Therapeutics Valuation Multiples
Monopar Therapeutics trades at (10.6x) EV/EBITDA.
Monopar Therapeutics Financial Valuation Multiples
As of April 11, 2026, Monopar Therapeutics has market cap of $388M and EV of $247M.
Equity research analysts estimate Monopar Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Monopar Therapeutics has a P/E ratio of (20.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $388M | XXX | $388M | XXX | XXX | XXX |
| EV (current) | $247M | XXX | $247M | XXX | XXX | XXX |
| EV/EBITDA | (10.6x) | XXX | (14.8x) | XXX | XXX | XXX |
| EV/EBIT | (11.2x) | XXX | (14.8x) | XXX | XXX | XXX |
| P/E | (20.4x) | XXX | (28.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Monopar Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Monopar Therapeutics Margins & Growth Rates
Monopar Therapeutics' revenue in the last fiscal year grew by —.
Monopar Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Monopar Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 58% | XXX | 144% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Monopar Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Formycon | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Ever Supreme Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Opus Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Monopar Therapeutics M&A Activity
Monopar Therapeutics acquired XXX companies to date.
Last acquisition by Monopar Therapeutics was on XXXXXXXX, XXXXX. Monopar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Monopar Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMonopar Therapeutics Investment Activity
Monopar Therapeutics invested in XXX companies to date.
Monopar Therapeutics made its latest investment on XXXXXXXX, XXXXX. Monopar Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Monopar Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Monopar Therapeutics
| When was Monopar Therapeutics founded? | Monopar Therapeutics was founded in 2014. |
| Where is Monopar Therapeutics headquartered? | Monopar Therapeutics is headquartered in United States. |
| How many employees does Monopar Therapeutics have? | As of today, Monopar Therapeutics has over 16 employees. |
| Who is the CEO of Monopar Therapeutics? | Monopar Therapeutics' CEO is Chandler D. Robinson. |
| Is Monopar Therapeutics publicly listed? | Yes, Monopar Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Monopar Therapeutics? | Monopar Therapeutics trades under MNPR ticker. |
| When did Monopar Therapeutics go public? | Monopar Therapeutics went public in 2019. |
| Who are competitors of Monopar Therapeutics? | Monopar Therapeutics main competitors are Formycon, PureTech Health, Ever Supreme Bio Technology, Climb Bio. |
| What is the current market cap of Monopar Therapeutics? | Monopar Therapeutics' current market cap is $388M. |
| Is Monopar Therapeutics profitable? | No, Monopar Therapeutics is not profitable. |
| What is the current EBITDA of Monopar Therapeutics? | Monopar Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Monopar Therapeutics? | Current EBITDA multiple of Monopar Therapeutics is (10.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.